Source link : https://www.newshealth.biz/health-news/aflibercept-for-rop-shows-sustained-efficacy-at-age-3/
TOPLINE: A 0.4 mg dose of aflibercept in infancy to treat retinopathy of prematurity (ROP) shows sustained efficacy and safety at 3 years of age, according to research presented at EURETINA 2024. No significant ocular or systemic safety concerns were identified during follow-up, and retinal vascularization appeared complete in 80% of eyes by age 2 […]
Author : News Health
Publish date : 2024-10-02 18:28:49
Copyright for syndicated content belongs to the linked Source.
